Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2005) 10 OC13

SFE2005 Oral Communications Thyroid and pituitary (8 abstracts)

Effect of dopamine agonists on prolactinomas and normal pituitary, assessed by dynamic contrast enhanced magnetic resonance imaging

AM Manuchehri 1 , M Lowry 1 , LW Turnbull 1 , C Rowland-Hill 2 & SL Atkin 1


University of Hull, Hull, East Yorkshire, United Kingdom2, Hull & East Yorkshire NHS, Hull, East Yorkshire, United Kingdom.


Background: Dopamine agonists may act on prolactinoma size and secretion through additional effects on adenoma vascularity which can be visualised using Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI). To investigate this 23 subjects, 5 with macroprolactinomas (prolactin (PRL) range 14631-500000mU/L), 11 with microprolactinomas (PRL range 621-4777mU/L), 7 individuals with non-lesion hyperprolactinemia and 15 normal volunteers, including 5 females on oral contraceptive pills were studied. Patients were treated with cabergoline 4 mg weekly for macroprolactinomas and quinagolide 75μg daily for microprolactinomas. DCE-MRIs were performed before treatment, at 3–4 days, 1 month and 3–4 months after treatment. Normal volunteers took three 75μg quinagolide doses and were rescanned after 3 days. Obtained data was analysed using Tofts and Kermode two compartment model, estimating vascular permeability and leakage space.

Results: A significant reduction in PRL levels was seen for all patients and volunteers. A significant decrease in vascular parameters was observed in both macroprolactinomas and microprolactinomas which was maintained during the treatment period (p<0.01). No difference in pituitary vessel permeability was demonstrated for normal volunteers or subjects with non-lesion hyperprolactinemia either before or after 3 days treatment. 4 of 5 macroprolactinomas demonstrated a decrease in permeability of 75% at 1 month (p<0.0001) with a reduction in tumour size, which continued to decrease at 4 months. The single macroprolactinoma not showing a change in permeability was unchanged in size after 4 months treatment.

Conclusion: The functional vascularity of prolactinoma differs from non-lesion hyperprolactinaemic and normal pituitary, and is responsive to dopamine agonist therapy. The reduction in vascular parameters is a crucial step in macroadenoma shrinkage and precedes shrinkage. Macroprolactinomas not showing an early DCE-MRI treatment response may represent dopamine agonist resistance, requiring early surgery.

Volume 10

196th Meeting of the Society for Endocrinology and Society for Endocrinology joint Endocrinology and Diabetes Day

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.